<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101654580</journal-id>
<journal-id journal-id-type="pubmed-jr-id">43689</journal-id>
<journal-id journal-id-type="nlm-ta">ACS Infect Dis</journal-id>
<journal-id journal-id-type="iso-abbrev">ACS Infect Dis</journal-id>
<journal-title-group>
<journal-title>ACS infectious diseases</journal-title>
</journal-title-group>
<issn pub-type="epub">2373-8227</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29275629</article-id>
<article-id pub-id-type="pmc">5893282</article-id>
<article-id pub-id-type="doi">10.1021/acsinfecdis.7b00122</article-id>
<article-id pub-id-type="manuscript">NIHMS955618</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Inhibitors of LexA autoproteolysis and the bacterial SOS response discovered by an academic-industry partnership</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Mo</surname>
<given-names>Charlie Y.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Culyba</surname>
<given-names>Matthew J.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Selwood</surname>
<given-names>Trevor</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kubiak</surname>
<given-names>Jeffrey M.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hostetler</surname>
<given-names>Zachary M.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jurewicz</surname>
<given-names>Anthony J.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Keller</surname>
<given-names>Paul M.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pope</surname>
<given-names>Andrew J.</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Quinn</surname>
<given-names>Amy</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schneck</surname>
<given-names>Jessica</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Widdowson</surname>
<given-names>Katherine L.</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kohli</surname>
<given-names>Rahul M.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Department of Medicine, Biochemistry &amp; Biophysics, University of Pennsylvania, 3610 Hamilton Walk, Philadelphia, PA, 19104</aff>
<aff id="A2">
<label>2</label>Screening, Profiling, and Mechanistic Biology, GlaxoSmithKline, 1250 S. Collegeville, Collegeville, PA 19426</aff>
<aff id="A3">
<label>3</label>Discovery Partnerships with Academia, GlaxoSmithKline, 1250 S. Collegeville, Collegeville, PA 19426</aff>
<author-notes>
<corresp id="FN1"><label>*</label>Corresponding author: <email>rkohli@pennmedicine.upenn.edu</email></corresp>
<fn fn-type="present-address" id="FN2">
<p><italic>Current address.</italic> C.Y.M.: Laboratory of Bacteriology, The Rockefeller University, New York, NY; M.J.C.: Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, PA.</p>
</fn>
<fn fn-type="COI-statement" id="FN4">
<p>
<bold>CONFLICTS OF INTEREST</bold>
</p>
<p>A.J.J., P.M.K., A.J.P., A.Q., J.S., and K.L.W are employees of GlaxoSmithKline.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>30</day>
<month>3</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>08</day>
<month>1</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<day>09</day>
<month>3</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>09</day>
<month>3</month>
<year>2019</year>
</pub-date>
<volume>4</volume>
<issue>3</issue>
<fpage>349</fpage>
<lpage>359</lpage>
<!--elocation-id from pubmed: 10.1021/acsinfecdis.7b00122-->
<abstract id="Abs1">
<p id="P1">The RecA/LexA axis of the bacterial DNA damage (SOS) response is a promising, yet non-traditional drug target. The SOS response is initiated upon genotoxic stress, when RecA, a DNA damage sensor, induces LexA, the SOS repressor, to undergo autoproteolysis, thereby de-repressing downstream genes that can mediate DNA repair and accelerate mutagenesis. As genetic inhibition of the SOS response sensitizes bacteria to DNA damaging antibiotics and decreases acquired resistance, inhibitors of the RecA/LexA axis could potentiate our current antibiotic arsenal. Compounds targeting RecA, which has many mammalian homologs, have been reported; however, small-molecules targeting LexA autoproteolysis, a reaction unique to the prokaryotic SOS response, have remained elusive. Here, we describe the logistics and accomplishments of an academic-industry partnership formed to pursue inhibitors against the RecA/LexA axis. A novel fluorescence polarization assay reporting on RecA-induced self-cleavage of LexA enabled the screening of 1.8 million compounds. Follow-up studies on select leads show distinct activity patterns in orthogonal assays, including several with activity in cell-based assays reporting on SOS activation. Mechanistic assays demonstrate that we have identified first-in-class small molecules that specifically target the LexA autoproteolysis step in SOS activation. Our efforts establish a realistic example for navigating academic-industry partnerships in pursuit of anti-infective drugs, and offer starting points for dedicated lead optimization of SOS inhibitors that could act as adjuvants for current antibiotics.</p>
</abstract>
<abstract abstract-type="graphical" id="Abs2">
<title>Graphical Abstract</title>
<p id="P3">
<graphic orientation="portrait" position="anchor" xlink:href="nihms955618u1.jpg"></graphic></p>
</abstract>
<kwd-group>
<kwd>SOS response</kwd>
<kwd>LexA</kwd>
<kwd>RecA</kwd>
<kwd>antimicrobial resistance</kwd>
<kwd>anti-virulence</kwd>
<kwd>high-throughput screening</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>